0A5V Stock Overview Operates as a healthcare company worldwide. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Price History & Performance
Summary of share price highs, lows and changes for Viatris Historical stock prices Current Share Price US$12.40 52 Week High US$13.61 52 Week Low US$9.94 Beta 0.95 1 Month Change -6.52% 3 Month Change 8.70% 1 Year Change 17.10% 3 Year Change -9.36% 5 Year Change n/a Change since IPO -5.92%
Recent News & Updates
Viatris Inc. Announces Publication of Phase 2B Care Study Data for Cenerimod in Lancet Rheumatology Dec 18
Third quarter dividend of US$0.12 announced Nov 11
Third quarter 2024 earnings released: EPS: US$0.079 (vs US$0.28 in 3Q 2023) Nov 08
Viatris Inc. Declares Quarterly Dividend, Payable on December 13, 2024 Nov 05
Viatris Inc., Annual General Meeting, Dec 06, 2024 Oct 28 Viatris Inc. Announces Positive Top-Line Results from Phase 3 Study of Effexor® in Japanese Adults with Generalized Anxiety Disorder (GAD) Oct 09
See more updates
Viatris Inc. Announces Publication of Phase 2B Care Study Data for Cenerimod in Lancet Rheumatology Dec 18
Third quarter dividend of US$0.12 announced Nov 11
Third quarter 2024 earnings released: EPS: US$0.079 (vs US$0.28 in 3Q 2023) Nov 08
Viatris Inc. Declares Quarterly Dividend, Payable on December 13, 2024 Nov 05
Viatris Inc., Annual General Meeting, Dec 06, 2024 Oct 28 Viatris Inc. Announces Positive Top-Line Results from Phase 3 Study of Effexor® in Japanese Adults with Generalized Anxiety Disorder (GAD) Oct 09
Viatris Launches (Pr) Viagra ODF in Canada Oct 01
Viatris Inc. to Report Q3, 2024 Results on Nov 07, 2024 Sep 17
Director recently sold US$2.3m worth of stock Sep 15
Director recently sold US$3.5m worth of stock Aug 25
Viatris Inc. Presents Late Breaking Abstract on Cenerimod at the 26th Asia-Pacific League of Associations for Rheumatology Annual Congress Aug 23
Second quarter dividend of US$0.12 announced Aug 11
Second quarter 2024 earnings released: US$0.27 loss per share (vs US$0.22 profit in 2Q 2023) Aug 09
Viatris Inc. Revises Earnings Guidance for the Fiscal Year 2024 Aug 08
Viatris Inc. Declares Quarterly Dividend, Payable on September 13, 2024 Aug 06
Cooper Consumer Health SAS completed the acquisition of Substantially All of the Over-the-Counter Business of Viatris Inc. (NasdaqGS:VTRS). Jul 04
Director recently sold US$3.6m worth of stock Jun 18
Viatris Inc. to Report Q2, 2024 Results on Aug 08, 2024 Jun 10 IQuest Enterprises Private Limited acquired API operations of Viatris in India.
Chief Legal Officer recently sold US$928k worth of stock May 29
First quarter dividend of US$0.12 announced May 12 Viatris Inc. Announces Quarterly Dividend, Payable on June 14, 2024
First quarter 2024 earnings released: EPS: US$0.095 (vs US$0.19 in 1Q 2023) May 09
Viatris Inc. to Report Q1, 2024 Results on May 09, 2024 Apr 17 Viatris Inc. Announces Launch of First Bioequivalent Generic Version of Copaxone 20 mg/mL Once-Daily in Canada
Viatris Inc. Announces the Launch of RYZUMVI (Phentolamine Ophthalmic Solution) 0.75% in the United States Apr 02
President of Developed Markets recently sold US$3.0m worth of stock Mar 16
Insud Pharma S.L.U. acquired Women Healthcare business of Viatris Inc. (NasdaqGS:VTRS). Mar 13
Fourth quarter dividend of US$0.12 announced Mar 04
Viatris Inc. Declares Quarterly Dividend, Payable on March 18, 2024 Feb 29
Full year 2023 earnings released: EPS: US$0.046 (vs US$1.72 in FY 2022) Feb 29
Viatris Inc. to Report Fiscal Year 2023 Results on Feb 28, 2024 Feb 06
Viatris Announces CFO Changes Dec 17 Viatris Inc. Appoints Leo Groothuis to Serve on the Compliance and Risk Oversight Committee, Executive Committee and Governance and Sustainability Committee
Upcoming dividend of US$0.12 per share at 5.2% yield Nov 15
Viatris Inc. Declares Quarterly Dividend, Payable on December 15, 2023 Nov 08
Third quarter 2023 earnings released: EPS: US$0.28 (vs US$0.29 in 3Q 2022) Nov 08
Viatris Inc., Annual General Meeting, Dec 15, 2023 Nov 04
Viatris Inc. Announces That Its President, Rajiv Malik, Will Be Retiring as an Executive of the Company Effective April 1, 2024 Oct 21
Viatris Inc. to Report Q3, 2023 Results on Nov 07, 2023 Oct 11
Now 23% undervalued after recent price drop Oct 03
Viatris Inc. and Ocuphire Pharma, Inc. Announce Fda Approval of Ryzumvl™? (Phentolamine Ophthalmic Solution) 0.75% Eye Drops for the Treatment of Pharmacologically-Induced Mydriasis Produced by Adrenergic Agonists (E.G., Tropicamide) Agents Sep 28
Viatris Reportedly in Talks to Sell European OTC Assets to CVC Sep 07
Now 23% undervalued Sep 06
Viatris Inc. Announces U.S. FDA Tentative Approval of Paediatric Formulation of Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC), Once-Daily Treatment for Children Living with HIV Sep 06
Upcoming dividend of US$0.12 per share at 4.3% yield Aug 16 Viatris Inc. Declares Quarterly Dividend, Payable on September 15, 2023
Second quarter 2023 earnings released: EPS: US$0.22 (vs US$0.26 in 2Q 2022) Aug 07
Viatris Inc. and Kindeva Drug Delivery L.P. Announces Launch of Breyna (Budesonide and Formoterol Fumarate Dihydrate) Inhalation Aerosol Aug 01
Viatris Inc. to Report Q2, 2023 Results on Aug 07, 2023 Jun 29
Holzer & Holzer, LLC Announces A Class Action Lawsuit Has Been Filed Against Viatris Inc Jun 21 Viatris Inc. Announces Board Changes May 23
Johnson Fistel, LLP Files Class Action Lawsuit Against Viatris Inc May 17
Upcoming dividend of US$0.12 per share at 5.1% yield May 16
First quarter 2023 earnings released: EPS: US$0.19 (vs US$0.33 in 1Q 2022) May 09 Viatris Inc. Reaffirms Revenue Guidance for the Full-Year 2023
Full year 2022 earnings released: EPS: US$1.72 (vs US$1.05 loss in FY 2021) Feb 28
Biocon Plans to Sell Stake in Biologics Arm to Pare Debt Feb 17
Viatris Inc. to Report Q4, 2022 Results on Feb 27, 2023 Feb 16 Viatris Inc. (NasdaqGS:VTRS) completed the acquisition of Oyster Point Pharma, Inc. (NasdaqGS:OYST) from a group of shareholders.
Viatris Inc. Announces Changes to its Board Dec 30
Viatris Inc. Announces Approval of Emissions Reduction Targets by the Science Based Target Initiative Dec 15
Biocon Biologics Limited completed the acquisition of biosimilars portfolio and related commercial and operational capabilities from Viatris Inc. (NasdaqGS:VTRS). Nov 30
Upcoming dividend of US$0.12 per share Nov 16 Viatris Inc. (NasdaqGS:VTRS) entered into a definitive agreement to acquire Oyster Point Pharma, Inc. (NasdaqGS:OYST) for approximately $300 million.
Third quarter 2022 earnings released: EPS: US$0.29 (vs US$0.26 in 3Q 2021) Nov 08 Viatris Inc. Reaffirms Revenue Guidance for the Full Year 2022
Viatris Inc., Annual General Meeting, Dec 09, 2022 Oct 31
Viatris Inc., Annual General Meeting, Dec 09, 2022 Oct 29
Viatris Inc. to Report Q3, 2022 Results on Nov 07, 2022 Oct 25
Viatris Reportedly Considers Sale of $3 Billion European OTC Assets Oct 13
Independent Non-Executive Director recently sold US$100k worth of stock Aug 21
Upcoming dividend of US$0.12 per share Aug 16
Viatris Inc. Declares Quarterly Dividend, Payable on September 16, 2022 Aug 09
Second quarter 2022 earnings released: EPS: US$0.26 (vs US$0.23 loss in 2Q 2021) Aug 08
Viatris Inc. to Report Q2, 2022 Results on Aug 08, 2022 Jul 02
Insider recently sold US$106k worth of stock May 28
First quarter 2022 earnings released: EPS: US$0.33 (vs US$0.86 loss in 1Q 2021) May 10 Viatris Declares Quarterly Dividend, Payable on June 16, 2022 May 10
Viatris Inc. to Report Q1, 2022 Results on May 09, 2022 Apr 09
Executive Chairman of the Board recently sold US$5.1m worth of stock Mar 13 Viatris Inc. (NasdaqGS:VTRS) announces an Equity Buyback for $1,000 million worth of its shares. Mar 01
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Mar 01 Viatris Inc. Provides Earnings Guidance for the Fiscal Year 2022 Shareholder Returns 0A5V GB Pharmaceuticals GB Market 7D -1.2% -1.7% -2.6% 1Y 17.1% -3.5% 2.4%
See full shareholder returns
Return vs Market: 0A5V exceeded the UK Market which returned 2.4% over the past year.
Price Volatility Is 0A5V's price volatile compared to industry and market? 0A5V volatility 0A5V Average Weekly Movement 5.5% Pharmaceuticals Industry Average Movement 6.1% Market Average Movement 4.8% 10% most volatile stocks in GB Market 10.7% 10% least volatile stocks in GB Market 2.6%
Stable Share Price: 0A5V has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: 0A5V's weekly volatility (5%) has been stable over the past year.
About the Company Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs).
Show more Viatris Inc. Fundamentals Summary How do Viatris's earnings and revenue compare to its market cap? 0A5V fundamental statistics Market cap US$14.94b Earnings (TTM ) -US$883.30m Revenue (TTM ) US$15.05b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 0A5V income statement (TTM ) Revenue US$15.05b Cost of Revenue US$8.72b Gross Profit US$6.32b Other Expenses US$7.21b Earnings -US$883.30m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.74 Gross Margin 42.03% Net Profit Margin -5.87% Debt/Equity Ratio 79.5%
How did 0A5V perform over the long term?
See historical performance and comparison Dividends
3.8% Current Dividend Yield
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/21 17:54 End of Day Share Price 2024/12/20 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Viatris Inc. is covered by 44 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Jasper Hellweg Argus Research Company Ishan Majumdar Baptista Research Richard Silver Barclays
Show 41 more analysts 